01 Jul 2019 --- Microbiome human discovery platform, DayTwo, has raised US$31 million in series B financing. DayTwo, which offers a glycemic control solution for people with Type 2 diabetes, will use the funding to accelerate go-to-market initiatives in the US, where the company partners with payers, providers and employers, and to continue to develop a new generation of products and services for metabolic and gastrointestinal conditions. The financing brings DayTwo’s total funding to US$48 million.
